Skip Navigation


Hum. Reprod. Advance Access originally published online on November 11, 2004
Human Reproduction 2005 20(2):563-568; doi:10.1093/humrep/deh612
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF ) Freely available
Right arrow All Versions of this Article:
20/2/563    most recent
deh612v2
deh612v1
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (11)
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by van Vliet, H. A.A.M.
Right arrow Articles by Helmerhorst, F. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by van Vliet, H. A.A.M.
Right arrow Articles by Helmerhorst, F. M.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Human Reproduction vol. 20 no. 2 © European Society of Human Reproduction and Embryology 2004; all rights reserved

Association between sex hormone-binding globulin levels and activated protein C resistance in explaining the risk of thrombosis in users of oral contraceptives containing different progestogens

Huib A.A.M. van Vliet1, Marijke Frolich2, M. Christella4, L.G.D. Thomassen4, Carine J.M. Doggen3, Frits R. Rosendaal3, Jan Rosing4 and Frans M. Helmerhorst1,5

1 Department of Gynaecology and Reproductive Medicine, 2 Department of Clinical Chemistry, 3 Department of Hematology and Clinical Epidemiology, Leiden University Medical Center, P.O.Box 9600, 2300 RC Leiden and 4 Department of Biochemistry, Cardiovascular Research Institute Maastricht, Maastricht University, P.O.Box 616, 6200 MD Maastricht, The Netherlands

5 To whom correspondence should be addressed. Email: f.m.helmerhorst{at}lumc.nl

BACKGROUND: Epidemiological studies have shown that both the estrogen dose and progestogen type of oral contraceptives contribute to the increased risk of thrombosis in oral contraceptive users. Thrombin generation-based activated protein C (APC) sensitivity is a global test for the net prothrombotic effect of oral contraceptives and predicts the thrombotic risk. Our objective was to test the usefulness of sex hormone-binding globulin (SHBG) as a marker for the thrombotic risk of an oral contraceptive. METHODS: We measured SHBG and APC resistance in 156 healthy users of various types of oral contraceptives. RESULTS: Users of oral contraceptives with a moderately increased risk of thrombosis (gestodene and desogestrel pills) had higher SHBG levels than users of low-risk oral contraceptives containing levonorgestrel. Similarly, for higher doses of estrogen in oral contraceptives we found higher SHBG levels. Women using oral contraceptives with the highest thrombotic risk (cyproterone acetate pills) rendered the highest SHBG levels. Users of oral contraceptives containing gestodene, desogestrel or cyproterone acetate were more resistant to APC than users of levonorgestrel pills. SHBG levels were positively associated with the increased APC resistance. CONCLUSIONS: Our findings support the hypothesis that the effect of an oral contraceptive on SHBG levels might be a marker for the thrombotic risk.

Key words: APC resistance/oral contraceptives/SHBG/venous thrombosis


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 BMJHome page
A van Hylckama Vlieg, F M Helmerhorst, J P Vandenbroucke, C J M Doggen, and F R Rosendaal
The venous thrombotic risk of oral contraceptives, effects of oestrogen dose and progestogen type: results of the MEGA case-control study
BMJ, August 13, 2009; 339(aug13_2): b2921 - b2921.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
R. Sitruk-Ware, G. Plu-Bureau, J. Menard, J. Conard, S. Kumar, J.-C. Thalabard, B. Tokay, and P. Bouchard
Effects of Oral and Transvaginal Ethinyl Estradiol on Hemostatic Factors and Hepatic Proteins in a Randomized, Crossover Study
J. Clin. Endocrinol. Metab., June 1, 2007; 92(6): 2074 - 2079.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.